ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Poniard Pharmaceuticals Announces Picoplatin Safety Data In Colorectal Cancer
Poniard
Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused
on oncology, announced that it has presented safety data from a Phase
1 dose-escalation study of picoplatin, the Company's lead product
candidate, at the 2008 Gastrointestinal Cancers Symposium, a meeting of the
American Society of Clinical Oncology (ASCO) which is being held in
Orlando, Fla.
The poster presentation included safety data from a Phase 1 study of
picoplatin in combination with 5-fluorouracil (5FU) and leucovorin (LV) as
a first-line treatment for metastatic colorectal cancer (mCRC). The Phase 1
study seeks to establish the maximum tolerated dose of picoplatin and
provide information on the safety of picoplatin when combined with 5FU and
LV for the treatment of colorectal cancer. Promising safety data observed
from the study to date formed the basis for further development of
picoplatin in our ongoing Phase 2 trial in mCRC.
"These study results suggest that picoplatin does not cause severe
neurotoxicity, as is commonly seen in mCRC patients treated with the
regimen of 5FU and LV with oxaliplatin," said Jerry McMahon, Ph.D.,
chairman and CEO of Poniard Pharmaceuticals. "Picoplatin has demonstrated
both good tolerability and no severe neuropathies when combined with 5FU
and LV. We believe picoplatin has the potential to be a preferred platinum
for the treatment of colorectal and other cancer indications."
Current National Comprehensive Cancer Network (NCCN) guidelines
encourage the discontinuation of FOLFOX (5FU and LV with oxaliplatin) after
three months of therapy or sooner if significant (Grade 3 or greater)
neurotoxicity develops. For more information, please see
http://www.nccn.org.
In the Phase 1 study, 50 patients were treated with picoplatin on
either an every-two-week or an every-four-week basis in combination with
the standard of care every-two-week dose of 5FU and LV. Patients received
up to 28 cycles, and the therapy was well tolerated. Increased
hematological toxicity was observed at higher doses. None of the patients
treated with picoplatin exhibited a Grade 3 or higher neuropathy and only 9
of 45 patients (20 percent) experienced mild neuropathy. No neuropathy of
Grade 2 or greater was observed in the 26 patients who received greater
than or equal to 400 mg/m squared picoplatin. Mild nephro- and oto-
toxicity were observed infrequently. The dose limiting toxicity (DLT) was
most frequently hematological with neutropenia and thrombocytopenia. The
maximum tolerated dose was established in the every-four-week schedule at
150 mg/m squared. The maximum tolerated dose for the every-two-week
schedule has not yet been reached.
Based on the evidence of a more attractive safety profile of picoplatin
in this combination (FOLPI) compared to the standard of care regimen with
oxaliplatin (FOLFOX) as well as clinical activity in the Phase 1 study, the
Company initiated a randomized Phase 2 trial in November, 2007 to evaluate
intravenous picoplatin in the first-line treatment of mCRC. The Phase 2
trial is intended to generate proof-of-concept data to further evaluate
efficacy and safety, including neuropathy of picoplatin in combination with
5-FU and LV (FOLPI versus FOLFOX) and to provide support for a potential
registrational Phase 3 trial. The Company expects to present data from the
Phase 1 and 2 mCRC program in scientific forums around mid year.
About Picoplatin
Picoplatin is an intravenous chemotherapeutic agent that has an
improved safety profile compared to existing platinum-based
chemotherapeutics. It was designed to overcome platinum resistance
associated with the treatment of solid tumors. Picoplatin has been
evaluated in more than 750 patients and has demonstrated activity in
multiple indications with no evidence of significant kidney, nerve toxicity
or hearing loss, toxicities commonly observed with other platinum
chemotherapy drugs.
In addition to the Phase 2 clinical trial in patients with mCRC,
Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3
trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in
small cell lung cancer. This registrational trial is being conducted under
a Special Protocol Assessment (SPA) from the U.S. Food and Drug
Administration (FDA) and is evaluating overall survival as the primary
endpoint. The Company also is evaluating intravenous picoplatin in an
ongoing Phase 2 clinical trial for the treatment of hormone refractory
prostate cancer (HRPC). Oral picoplatin is being evaluated in a Phase 1
clinical trial in solid tumors.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the development and commercialization of innovative oncology products to
impact the lives of people with cancer. Picoplatin, the Company's lead
platform product candidate, is a new generation platinum therapy with an
improved safety profile. Picoplatin is designed to overcome and prevent
platinum resistance associated with chemotherapy in solid tumors, and is
being studied in multiple cancer indications, combinations and
formulations. Clinical trials of intravenous picoplatin include a Phase 3
trial in small cell lung cancer and Phase 2 trials in metastatic colorectal
and hormone- refractory prostate cancer, as well as a clinical trial of
oral picoplatin in solid tumors. Picoplatin has not been approved by
regulatory authority for use in humans. For additional information please
visit http://www.poniard.com.
This release contains forward-looking statements, including statements
regarding the Company's business objectives and strategic goals, drug
development plans, results of clinical trials and the potential safety and
efficacy of its products in development. The Company's actual results may
differ materially from those indicated in these forward-looking statements
based on a number of factors, including risks and uncertainties associated
with the Company's research and development activities; the results of pre-
clinical and clinical testing; the receipt and timing of required
regulatory approvals; the market's acceptance of the Company's proposed
products; the Company's anticipated operating losses, need for future
capital and ability to obtain future funding; competition from third
parties; the Company's ability to preserve and protect intellectual
property rights; the Company's dependence on third-party manufacturers and
suppliers; the Company's lack of sales and marketing experience; the
Company's ability to attract and retain key personnel; changes in
technology, government regulation and general market conditions; and the
risks and uncertainties described in the Company's current and periodic
reports filed with the Securities and Exchange Commission, including the
Company's Annual Report on Form 10-K for the year ended December 31, 2006,
as amended, and most current Quarterly Report on Form 10-Q. Readers are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this release. The Company undertakes no
obligation to update any forward-looking statement to reflect new
information, events or circumstances after the date of this release or to
reflect the occurrence of unanticipated events.
(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard
Pharmaceuticals, Inc.
Poniard Pharmaceuticals, Inc.
http://www.poniard.com
Pumnal Pharmaceuticals Announces Picoplatin de siguranþã a datelor În cancerul colorectal - Poniard Pharmaceuticals Announces Picoplatin Safety Data In Colorectal Cancer - articole medicale engleza - startsanatate